Press Releases
January 24, 2022
Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2022 ASCO GI Meeting
Interim data presented in poster reflects median overall survival of 12.0 months, not yet final, and an objective response rate of 48%, both greater than historical rates reported for standard of care
View/download poster presentation »
December 14, 2021
Panbela Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines
Development Program for SBP-101’s Expansion into Ovarian Cancer Expected in 1H 2022
November 18, 2021
Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Gastrointestinal Cancers Symposium
November 10, 2021
Panbela Provides Business Update and Reports Q3 2021 Financial Results
October 25, 2021
Panbela Schedules Conference Call on Nov 10 to Report Q3 2021 Financial Results
September 7, 2021
Panbela to Present at Upcoming Investor Conferences
H.C. Wainwright 23rd Annual Global Investment Conference: September 13th to 15th, 2021
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: September 20-23
August 11, 2021
Panbela Provides Business Update and Reports Q2 2021 Financial Results
August 9, 2021
Panbela Announces Issuance of key U.S. Patent; Patent is for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd
July 28, 2021
Panbela Schedules Conference Call on August 11 to Report 2021 Second Quarter Financial Results
July 7, 2021